Changes in weight and glycemia after initiation of integrase strand transfer inhibitors among people with HIV and diabetes

Read full text Summarise with VIRAT
Authors: Yoseob Joseph Hwang, Catherine R. Lesko, Todd Tarquin Brown, G. Caleb Alexander, Keri N. Althoff, Oluwaseun O Falade-Nwulia, Richard D Moore, Lauren C. Zalla, Eva Tseng, John Robert Koethe, Peter F. Rebeiro, Vincent C. Marconi
+6 more Michael J. Silverberg, M. Horberg, Thibaut Davy-Méndez, Raynell Lang, Seble Kassaye, Anthony T. Fojo
Cited by: 0
References: 30

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

OBJECTIVE: Evaluate the impact of initiating integrase strand transfer inhibitor (INSTI) - vs. nonnucleoside reverse transcriptase inhibitor (NNRTI) - or protease inhibitor-based regimens on weight and glycemia among people with HIV (PWH) and type 2 diabetes. DESIGN: Cohort study. METHODS: From multisite HIV cohorts in the United States and Canada (2007-2022), we identified PWH with diabetes who newly initiated INSTI-based, NNRTI-based, or protease inhibitor-based therapy. We used inverse probability of treatment-weighted (IPTW) generalized linear models to compare changes in weight and hemoglobin A1c (HbA1c) at approximately 12 months after antiretroviral therapy (ART) initiation. We assessed time to at least 5% weight gain and to glucose-lowering therapy augmentation or HbA1c increase at least 0.5 percentage points with IPTW Cox regression. RESULTS: Among 1279 PWH with diabetes, 548 initiated an INSTI-based regimen, 511 an NNRTI-based regimen, and 220 a protease inhibitor-based regimen. Compared with NNRTI users, INSTI users had greater adjusted mean weight gain [2.1 kg; 95% confidence interval (CI), 1.1-3.1], while the difference in HbA1c change was modest (0.2%; 95% CI, 0.0-0.5); both changes were similar between INSTI and protease inhibitor users. INSTI users had higher risk of at least 5% weight gain [adjusted hazard ratio (aHR), 1.35; 95% CI, 1.15-1.59] and glucose-lowering therapy augmentation or HbA1c increase at least 0.5% (aHR, 1.19; 95% CI, 1.02-1.41) compared with NNRTI users although similar risk vs. protease inhibitor users. CONCLUSION: Among PWH with diabetes, initiating INSTIs conferred modestly greater weight gain and worse glycemic outcomes vs. NNRTIs, but outcomes comparable to PIs, which is recognized for adverse metabolic effects. These findings inform the metabolic implications of INSTIs and support clinical monitoring after ART initiation.

Fields of Study & Subjects

HIV-related health complications and treatments HIV/AIDS drug development and treatment HIV/AIDS Research and Interventions

Publication details

Journal / source
AIDS
Volume
40
Issue
8
Pages
1180–1189
Publication date
24 March 2026
Language
EN